Chemoprevention of mammary carcinogenesis in a transgenic mouse model by α-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity

Oncogene

Volumn 22, Issue 17, 2003, Pages 2568-2572

  Li, Minglin ^a   Ren, Shuxun ^a   Tilli, Maddalena T ^a,b   Flaws, Jodi A ^c   Lubet, Ronald ^d   Grubbs, Clinton J ^e   Furth, Priscilla A ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apoptosis; Cell proliferation; Cyclin D1; DFMO; Mammary cancer progression; Transgenic mouse model

Indexed keywords

CYCLIN D1; EFLORNITHINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; GENE ACTIVITY; GROWTH INHIBITION; LATENT PERIOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLIN D1; EFLORNITHINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; MILK PROTEINS; PROMOTER REGIONS (GENETICS);

ANIMALIA; MUS MUSCULUS;

EID: 0037854593     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206314     Document Type: Article

References (34)

1. Alt JR, Gladden AB and Diehl JA. (2002). J. Biol. Chem., 277, 8517-8523
2. Arbeit JM, Riley RR, Huey B, Porter C, Kelloff G, Lubet R, Ward JM and Pinkel D. (1999). Cancer Res., 59, 3610-3620.
3. Baldin V, Lukas J, Marcote MJ, Pagano M and Draetta G. (1993). Genes Dev., 7, 812-821.
4. Cooper RL, Goldman JM and Vandenbergh JG. (1993). Methods in Toxicology, Vol. 3B. Heindel JJ, Chapin RE (eds), Academic Press: San Diego, pp. 45-56.
5. Diehl JA, Cheng M, Roussel MF and Sherr CJ. (1998). Genes Dev., 12, 3499-3511.
6. Fozard JR, Part ML, Prakash NJ and Grove J. (1980). Eur. J. Pharmacol., 65, 379-391.
7. Furth PA. (1998). Dev. Biol. Stand., 94, 281-287.
8. Furth PA, Bar-Peled U, Li M, Lewis A, Laucirica R, Jager R, Weiher H and Russell RG. (1999). Oncogene, 18, 6589-6596.
9. Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G and Lubet R. (2001). Cancer Res., 61, 7449-7455.
10. Gupta S, Afaq F and Mukhtar H. (2002). Oncogene, 21, 3727-3738.
11. Hursting SD, Perkins SN, Phang JM and Barrett JC. (2001). J. Nutr., 131, 3092S-3094S.
12. Ioachim EE, Malamou-Mitsi V, Kamina SA, Goussia AC and Agnantis NJ. (2000). Anticancer Res., 20, 4221-4225.
13. Joe AK, Liu H, Suzui M, Vural ME, Xiao D and Weinstein IB. (2002). Clin. Cancer Res., 8, 893-903.
14. Kelloff CJ, Lubet RA, Lieberman R, Eisenhauser K, Steele VE, Crowell JA, Hawk ET, Boone CW and Sigman C. (1998). Cancer Epidem. Biomarkers Prevention, 7, 65-78.
15. Kingsnorth AN, Russell WE, McCann PP, Diekema KA and Malt RA. (1983). Cancer Res., 43, 4035-4038.
16. Li M, Hu J, Heermeier K, Hennighausen L and Furth PA. (1996). Cell Growth Diff., 7, 3-11.
17. Li M, Lewis B, Capuco A, Laucirca R and Furth PA. (2000). Oncogene, 19, 1010-1019.
18. Masuda M, Toh S, Koike K, Kuratomi Y, Suzui M, Deguchi A, Komiyama S and Weinstein IB. (2002). Jpn. J. Cancer Res., 93, 329-339.
19. Nandi S, Guzman RC and Yang J. (1995). Proc. Natl. Acad. Sci. USA, 92, 3650-3657.
20. Pegg AE, McGovern KA and Wiest L. (1987). Biochem. J., 241, 305-307.
21. Peralta Soler A, Gilliard G, Megosh L, George K and O'Brien TG. (1998). Cancer Res., 58, 1654-1659.
22. Pidgeon GP, Kandouz M, Meram A and Honn KV. (2002). Cancer Res., 62, 2721-2727.
23. Ratko TA, Detrisac CJ, Rao KV, Thomas CF, Kelloff GJ and Moon RC. (1990). Anticancer Res., 10, 67-72.
24. Reddy BS, Nayini J, Tokumo K, Rigotty S, Zang E and Kelloff G. (1990). Cancer Res., 50, 2562-2568.
25. Reddy PR and Rukmini V. (1981). Contraception, 24, 215-221.
26. Ren S, Li M, Cai H, Hudgins S and Furth PA. (2000). Contemp. Top. Lab. Animal Sci., 40, 27-30.
27. Ren S, Cai HR, Li M and Furth PA. (2002). Oncogene, 21, 4335-4339.
28. Russo IH and Russo J. (1996). Health Perspect., 104, 938-967.
29. Seufferlein T, Seckl MJ, Schwarz E, Beil M, van Wichert G, Baust H, Luhrs H, Schmid RM and Adler G. (2002). Br. J. Cancer, 86, 1188-1196.
30. Thompson HJ and Ronan AM. (1986). Carcinogenesis, 7, 2003-2006.
31. Tzeng YJ, Guhl E, Graessmann M and Graessmann A. (1993). Oncogene, 8, 1965-1971.
32. Yoshidome K, Shibata M-A, Couldrey C, Korach KS and Green JE. (2000). Cancer Res., 60, 6901-6910.
33. Zhai S, Senderowicz AM, Sausville EA and Figg WD. (2002). Ann. Pharmacother., 36, 905-911.
34. Zhang M, Shi Y, Magit D, Furth PA and Sager R. (2000). Oncogene, 19, 6053-6058.